#METABOLOMICS WORKBENCH  DATATRACK_ID:3891 STUDY_ID:ST002583 ANALYSIS_ID:AN004254
VERSION                          	1
CREATED_ON                       	04-27-2023
#PROJECT
PR:PROJECT_TITLE                 	MoTrPAC
PR:PROJECT_SUMMARY               	MoTrPAC is a national research consortium designed to discover and perform
PR:PROJECT_SUMMARY               	preliminary characterization of the range of molecular transducers (the
PR:PROJECT_SUMMARY               	"molecular map") that underlie the effects of physical activity in humans. The
PR:PROJECT_SUMMARY               	program's goal is to study the molecular changes that occur during and after
PR:PROJECT_SUMMARY               	exercise and ultimately to advance the understanding of how physical activity
PR:PROJECT_SUMMARY               	improves and preserves health. Preclinical and clinical studies will examine the
PR:PROJECT_SUMMARY               	systemic effects of endurance and resistance exercise across a range of ages and
PR:PROJECT_SUMMARY               	fitness levels by molecular probing of multiple tissues before and after acute
PR:PROJECT_SUMMARY               	and chronic exercise. This program is the largest targeted NIH investment of
PR:PROJECT_SUMMARY               	funds into the mechanisms of how physical activity improves health and prevents
PR:PROJECT_SUMMARY               	disease. The MoTrPAC program is supported by the NIH Common Fund and is managed
PR:PROJECT_SUMMARY               	by a trans-agency working group representing multiple NIH institutes and
PR:PROJECT_SUMMARY               	centers, led by the NIH Office of Strategic Coordination, National Institute of
PR:PROJECT_SUMMARY               	Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes
PR:PROJECT_SUMMARY               	and Digestive and Kidney Diseases, National Institute on Aging, and National
PR:PROJECT_SUMMARY               	Institute of Biomedical Imaging and Bioengineering. MoTrPAC Steering Committee:
PR:PROJECT_SUMMARY               	Wendy Kohrt, Chair, Russ Tracy, Co-Chair; NIH Program Manager, Concepcion
PR:PROJECT_SUMMARY               	Nierras. Euan Ashley and Matthew Wheeler are the PIs for the Motrpac
PR:PROJECT_SUMMARY               	Bioinformatics / Data Coordination Center.
PR:INSTITUTE                     	MoTrPAC
PR:LAST_NAME                     	Ashley
PR:FIRST_NAME                    	Euan
PR:ADDRESS                       	Falk Building CV267, 870 Quarry Road, Stanford, California 94305
PR:EMAIL                         	motrpac-data-deposition@lists.stanford.edu
PR:PHONE                         	(650) 725-1846
PR:DOI                           	http://dx.doi.org/10.21228/M8V97D
#STUDY
ST:STUDY_TITLE                   	MoTrPAC: Endurance exercise training study in young adult rats, Rat Plasma -
ST:STUDY_TITLE                   	Targeted Tricarboxylic Acid Cycle
ST:STUDY_SUMMARY                 	The goal of the endurance exercise training study in young adult rats (internal
ST:STUDY_SUMMARY                 	code: PASS1B-06) was to perform exercise training studies in adult (6 month)
ST:STUDY_SUMMARY                 	F344 rats, and from these rats collect as many tissues as feasible in order to
ST:STUDY_SUMMARY                 	provide high quality samples for detailed analysis by chemical analysis sites.
ST:STUDY_SUMMARY                 	Tissues were collected from 10-12 rats sedentary control rats concurrent with
ST:STUDY_SUMMARY                 	the collection of the 8-week training groups. The 8-week training group and
ST:STUDY_SUMMARY                 	controls were from the same cohort and same age at euthanasia (either 8). For
ST:STUDY_SUMMARY                 	the older age group, an additional set of controls (n=5-6) were collected with
ST:STUDY_SUMMARY                 	the 1-2 week training group. Rats were either sedentary or underwent an exercise
ST:STUDY_SUMMARY                 	training program. Rats were exercised on the rodent treadmill 5 days per week
ST:STUDY_SUMMARY                 	using a progressive training protocol designed to exercise the rats at
ST:STUDY_SUMMARY                 	approximately 70% of VO2max as outlined in the Table on the next page. Training
ST:STUDY_SUMMARY                 	was performed no earlier than 10:00 am and no later than 5:00 pm over 5
ST:STUDY_SUMMARY                 	consecutive days per week. Training was initiated with the treadmill set at 70%
ST:STUDY_SUMMARY                 	of VO2 max (see tables) and 5 degrees grade for 20 minutes. The duration of
ST:STUDY_SUMMARY                 	exercise was increased by one minute each day until day 31 of training (start of
ST:STUDY_SUMMARY                 	week 7), when a duration of 50 min was reached. Speed and grade of each training
ST:STUDY_SUMMARY                 	session increased in larger increments due to treadmill parameters. The highest
ST:STUDY_SUMMARY                 	intensity and duration of training began on day 31. This intensity was
ST:STUDY_SUMMARY                 	maintained for the final 10 days of the protocol to ensure steady state had been
ST:STUDY_SUMMARY                 	achieved. If any rats were unable to perform at least 4 days of training per
ST:STUDY_SUMMARY                 	week they were removed from the study and euthanized. It is important to note
ST:STUDY_SUMMARY                 	that the starting treadmill speed varied depending on the sex and age of the
ST:STUDY_SUMMARY                 	rat. The initial and maximum speeds were based on VO2max measurements obtained
ST:STUDY_SUMMARY                 	during the pre-training testing of the compliant rats. Rats assigned to the
ST:STUDY_SUMMARY                 	control group followed a schedule similar to the training group. They were
ST:STUDY_SUMMARY                 	placed in one lane on the treadmill for 15 minutes/day, 5 days per week. The
ST:STUDY_SUMMARY                 	treadmill was set at 0 m/min at an incline that corresponded to the incline
ST:STUDY_SUMMARY                 	being used by the training group.
ST:INSTITUTE                     	Mayo Clinic
ST:DEPARTMENT                    	Internal Medicine
ST:LABORATORY                    	Mayo Clinic Metabolomics Resource Core (MCMRC)
ST:LAST_NAME                     	Nair
ST:FIRST_NAME                    	K. Sreekumaran
ST:ADDRESS                       	200 1st St SW, Rochester, MN 55902
ST:EMAIL                         	nair@mayo.edu
ST:PHONE                         	(507) 284-2511
ST:SUBMIT_DATE                   	2023-04-25
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Rattus norvegicus
SU:TAXONOMY_ID                   	10116
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	1628FB23-6F66-47D4-8D82-63C87726F0FD	90245013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_22.D.zip
SUBJECT_SAMPLE_FACTORS           	69FD4884-786D-4F2A-97B1-6174FBD25D60	90248013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_23.D.zip
SUBJECT_SAMPLE_FACTORS           	07AF7369-F082-4CA7-99D5-D973F4A162C9	90252013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_51.D.zip
SUBJECT_SAMPLE_FACTORS           	F9BEE1FA-E2DB-4BE4-A79C-99D585D6FD17	90265013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_29.D.zip
SUBJECT_SAMPLE_FACTORS           	A77AC89A-1D9E-4516-9DA4-2BE99C8126EF	90266013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_30.D.zip
SUBJECT_SAMPLE_FACTORS           	BC49E4EF-E2FE-4269-BAF0-461F768BD95D	90217013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_12.D.zip
SUBJECT_SAMPLE_FACTORS           	0559B193-BED3-4170-B045-10A2B6441CB6	90229013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_18.D.zip
SUBJECT_SAMPLE_FACTORS           	90CFE5A4-76FE-4458-A2B1-A66F0B60118E	90232013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_19.D.zip
SUBJECT_SAMPLE_FACTORS           	F0D83B29-8EFA-4CDE-B1AA-2358AC220ECF	90237013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_20.D.zip
SUBJECT_SAMPLE_FACTORS           	FCE9ABE6-B60B-4934-BAE5-56AF8B11ECEC	90239013110	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_21.D.zip
SUBJECT_SAMPLE_FACTORS           	B73AB139-7210-4498-9CCF-E1DBE6EBA71C	90559013110	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=15dec20_33.D.zip
SUBJECT_SAMPLE_FACTORS           	EA5C8932-9325-4DA5-96BB-50CD49CEDD10	90560013110	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=15dec20_34.D.zip
SUBJECT_SAMPLE_FACTORS           	0645F621-878C-4C9B-84A6-58862BAA17D9	90564013110	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=15dec20_35.D.zip
SUBJECT_SAMPLE_FACTORS           	68083256-8DAA-4185-B446-0CAF600474B5	90567013110	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=15dec20_36.D.zip
SUBJECT_SAMPLE_FACTORS           	6A013AA1-4D1E-4B75-B691-6BA22D928E51	90571013110	Group:Training | Timepoint:1 week of training or control time | Sex:Female	raw_file=15dec20_37.D.zip
SUBJECT_SAMPLE_FACTORS           	6D680EA2-C62B-4A35-8B6E-2ED6A79CB017	90421013110	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=15dec20_23.D.zip
SUBJECT_SAMPLE_FACTORS           	53F914B0-FD4F-4340-84A6-48341EAB3798	90422013110	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=15dec20_24.D.zip
SUBJECT_SAMPLE_FACTORS           	D350D633-8D95-4783-99F2-BB8294D2EC32	90423013110	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=15dec20_25.D.zip
SUBJECT_SAMPLE_FACTORS           	0DBFEB04-1B58-43CF-BAFD-9AA9915B67F6	90426013110	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=15dec20_26.D.zip
SUBJECT_SAMPLE_FACTORS           	10E282EB-1DBA-406E-BD5D-81027083A01D	90430013110	Group:Training | Timepoint:1 week of training or control time | Sex:Male	raw_file=15dec20_27.D.zip
SUBJECT_SAMPLE_FACTORS           	B137E81D-A9DE-4E3A-8E2B-AD6C22920B7E	90576013110	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=15dec20_38.D.zip
SUBJECT_SAMPLE_FACTORS           	DC8B35E8-4AA8-4829-8569-F223D069620C	90578013110	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=15dec20_39.D.zip
SUBJECT_SAMPLE_FACTORS           	8904857C-2073-4BBA-AC7C-1EC239E5BFF7	90581013110	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=15dec20_40.D.zip
SUBJECT_SAMPLE_FACTORS           	1F9BD644-303F-43E7-94BE-FF6654306F5E	90585013110	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=15dec20_41.D.zip
SUBJECT_SAMPLE_FACTORS           	0409BED3-F9FE-4C06-9920-74F5E5CA04A3	90587013110	Group:Training | Timepoint:2 weeks of training | Sex:Female	raw_file=15dec20_42.D.zip
SUBJECT_SAMPLE_FACTORS           	4E974304-21EB-42E8-A729-A7FB6B406E64	90439013110	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=15dec20_28.D.zip
SUBJECT_SAMPLE_FACTORS           	6527EC12-E7EB-4F17-BF0A-0AC7CD1819A0	90441013110	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=15dec20_29.D.zip
SUBJECT_SAMPLE_FACTORS           	AEB1611A-F29E-43F8-B9F3-A2BC4F9EB504	90444013110	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=15dec20_30.D.zip
SUBJECT_SAMPLE_FACTORS           	FDA87A8D-3634-4C42-9A1A-0EA03B58BB01	90449013110	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=15dec20_31.D.zip
SUBJECT_SAMPLE_FACTORS           	CDCFA3F1-07ED-4737-A36D-15EFEC325AA5	90450013110	Group:Training | Timepoint:2 weeks of training | Sex:Male	raw_file=15dec20_32.D.zip
SUBJECT_SAMPLE_FACTORS           	2E37478F-525F-4E5E-A882-EE75FD0CFB29	90406013110	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=15dec20_18.D.zip
SUBJECT_SAMPLE_FACTORS           	A9CE3E3D-31A0-4443-8A7F-8FD831D79248	90410013110	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=15dec20_19.D.zip
SUBJECT_SAMPLE_FACTORS           	3D5BC47C-BB3D-45A2-8DB8-D7ADCD51997C	90412013110	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=15dec20_20.D.zip
SUBJECT_SAMPLE_FACTORS           	89D6F615-D17C-4EB9-88EB-A602940FF179	90416013110	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=15dec20_21.D.zip
SUBJECT_SAMPLE_FACTORS           	FE012DC0-AF32-4C70-A4D4-F042B8BC4EC6	90420013110	Group:Training | Timepoint:4 weeks of training | Sex:Female	raw_file=15dec20_22.D.zip
SUBJECT_SAMPLE_FACTORS           	22D700B9-EDD0-4BC8-8155-EB9C39417F81	90280013110	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=16dec20_32.D.zip
SUBJECT_SAMPLE_FACTORS           	1CA4210C-3CE6-4A5A-996B-673EBDEB3B81	90281013110	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=16dec20_33.D.zip
SUBJECT_SAMPLE_FACTORS           	9F3E1040-D409-421E-B635-2572DC20ED89	90283013110	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=16dec20_34.D.zip
SUBJECT_SAMPLE_FACTORS           	569A9229-04E8-414A-A195-FE9E8F1B66AB	90289013110	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=16dec20_35.D.zip
SUBJECT_SAMPLE_FACTORS           	E4271AF1-899A-4A65-9D8D-BF18CEE3F1CF	90292013110	Group:Training | Timepoint:4 weeks of training | Sex:Male	raw_file=16dec20_36.D.zip
SUBJECT_SAMPLE_FACTORS           	0D5071F5-D166-4CF1-BE8B-EB4DF6E04C0E	90251013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_24.D.zip
SUBJECT_SAMPLE_FACTORS           	2479BEE5-2A38-4D09-B15B-B1715F561A9F	90254013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_26.D.zip
SUBJECT_SAMPLE_FACTORS           	0A4A7935-3AF4-463F-84E3-DCF07671509D	90258013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_52.D.zip
SUBJECT_SAMPLE_FACTORS           	04C84D7E-FC8C-422F-AE4B-CAFADB63407B	90259013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_28.D.zip
SUBJECT_SAMPLE_FACTORS           	2B969165-1A52-43AA-8FD9-39AFA62F094F	90267013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	raw_file=16dec20_31.D.zip
SUBJECT_SAMPLE_FACTORS           	0BD282C7-7832-4581-9089-08A32D557034	90218013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_13.D.zip
SUBJECT_SAMPLE_FACTORS           	955498F4-70A0-4D50-A2BA-619A8FED8FEF	90222013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_14.D.zip
SUBJECT_SAMPLE_FACTORS           	CFE06932-9314-4BCC-B2D9-73883D5FCDFB	90223013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_15.D.zip
SUBJECT_SAMPLE_FACTORS           	3719CB62-B551-49BE-94A0-E51DFE13D30D	90225013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_16.D.zip
SUBJECT_SAMPLE_FACTORS           	F65955CE-E49F-48C7-B861-02A2FDF6F9B8	90227013110	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	raw_file=16dec20_17.D.zip
#COLLECTION
CO:SAMPLE_TYPE                   	Plasma
#TREATMENT
TR:TREATMENT_SUMMARY             	-
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	homogenized in PBS, isotope IS added, deproteinized, 2 steps derivatization with
SP:SAMPLEPREP_SUMMARY            	ethoxamine, MTBSTFA
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Analytes were chromatographically separated with 17 minutes GC gradient
CH:INSTRUMENT_NAME               	Agilent Intuvo 9000 GC
CH:COLUMN_NAME                   	Agilent HP-5MS (30m x 0.250mm, 0.25um)
CH:CHROMATOGRAPHY_TYPE           	GC
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 5977B HES MSD
MS:INSTRUMENT_TYPE               	Single quadrupole
MS:MS_TYPE                       	EI
MS:MS_COMMENTS                   	SIM; peak integration, concentrations calculated
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	micromolar
MS_METABOLITE_DATA_START
Samples	90245013110	90248013110	90252013110	90265013110	90266013110	90217013110	90229013110	90232013110	90237013110	90239013110	90559013110	90560013110	90564013110	90567013110	90571013110	90421013110	90422013110	90423013110	90426013110	90430013110	90576013110	90578013110	90581013110	90585013110	90587013110	90439013110	90441013110	90444013110	90449013110	90450013110	90406013110	90410013110	90412013110	90416013110	90420013110	90280013110	90281013110	90283013110	90289013110	90292013110	90251013110	90254013110	90258013110	90259013110	90267013110	90218013110	90222013110	90223013110	90225013110	90227013110
Factors	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	Group:Control | Timepoint:8 weeks of training or control time | Sex:Female	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	Group:Control | Timepoint:8 weeks of training or control time | Sex:Male	Group:Training | Timepoint:1 week of training or control time | Sex:Female	Group:Training | Timepoint:1 week of training or control time | Sex:Female	Group:Training | Timepoint:1 week of training or control time | Sex:Female	Group:Training | Timepoint:1 week of training or control time | Sex:Female	Group:Training | Timepoint:1 week of training or control time | Sex:Female	Group:Training | Timepoint:1 week of training or control time | Sex:Male	Group:Training | Timepoint:1 week of training or control time | Sex:Male	Group:Training | Timepoint:1 week of training or control time | Sex:Male	Group:Training | Timepoint:1 week of training or control time | Sex:Male	Group:Training | Timepoint:1 week of training or control time | Sex:Male	Group:Training | Timepoint:2 weeks of training | Sex:Female	Group:Training | Timepoint:2 weeks of training | Sex:Female	Group:Training | Timepoint:2 weeks of training | Sex:Female	Group:Training | Timepoint:2 weeks of training | Sex:Female	Group:Training | Timepoint:2 weeks of training | Sex:Female	Group:Training | Timepoint:2 weeks of training | Sex:Male	Group:Training | Timepoint:2 weeks of training | Sex:Male	Group:Training | Timepoint:2 weeks of training | Sex:Male	Group:Training | Timepoint:2 weeks of training | Sex:Male	Group:Training | Timepoint:2 weeks of training | Sex:Male	Group:Training | Timepoint:4 weeks of training | Sex:Female	Group:Training | Timepoint:4 weeks of training | Sex:Female	Group:Training | Timepoint:4 weeks of training | Sex:Female	Group:Training | Timepoint:4 weeks of training | Sex:Female	Group:Training | Timepoint:4 weeks of training | Sex:Female	Group:Training | Timepoint:4 weeks of training | Sex:Male	Group:Training | Timepoint:4 weeks of training | Sex:Male	Group:Training | Timepoint:4 weeks of training | Sex:Male	Group:Training | Timepoint:4 weeks of training | Sex:Male	Group:Training | Timepoint:4 weeks of training | Sex:Male	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	Group:Training | Timepoint:8 weeks of training or control time | Sex:Female	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	Group:Training | Timepoint:8 weeks of training or control time | Sex:Male	
2-Hydroxyglutarate	2.7660	1.8320	2.0220	1.5320	2.2680	2.8100	1.1660	1.1280	2.1020	1.2840	1.3160	1.2360	1.7280	1.8280	1.0440	1.0540	0.9140	1.0600	1.4640	1.5820	1.5080	2.7840	1.8440	1.7420	2.1360	1.7940	1.0920	1.5600	1.3400	1.4720	1.3900	1.1160	1.3580	1.6480	1.4080	1.3920	1.6680	1.9540	2.1020	1.7960	1.5400	2.0120	2.0640	1.1480	1.7660	0.8260	1.3400	3.4060	1.3440	0.9640
Aspartate	4.0900	3.4620	3.2600	3.5100	9.6700	5.5140	4.0220	4.3980	14.8900	4.0040	5.5640	5.2120	7.1240	7.1720	8.7100	7.0220	5.4220	5.4620	6.3540	5.1260	6.5280	23.0360	6.5740	13.6040	8.2760	9.8900	6.6880	12.4020	7.5240	10.7960	5.9240	8.1440	6.5860	6.0960	9.9620	4.5420	11.9040	7.0120	4.0420	8.4840	3.2840	5.0520	4.3460	4.0700	6.1560	6.7180	5.0540	5.4480	3.5720	2.8480
cis-aconitate	5.6800	3.7240	3.5000	4.7880	5.0800	4.4160	3.7380	3.5160	3.9320	3.9540	4.2500	4.0320	4.6380	4.7920	5.0260	4.5640	3.7200	4.5300	4.1580	3.3220	4.3600	5.5960	4.4800	4.8580	4.8820	3.2160	3.9640	4.0800	4.3120	4.9000	3.1180	2.0600	3.5900	3.7580	3.6780	4.1280	4.5020	4.2840	4.7240	4.5600	3.8400	5.0680	3.7900	5.6540	4.6400	2.5180	3.1720	5.0200	3.3220	3.9460
Citrate	225.4900	210.4900	232.7520	172.6260	214.2380	174.5000	166.2940	158.5760	198.6440	154.0340	187.7040	174.0960	200.4100	214.2380	194.4260	176.5640	159.9080	160.0960	170.4200	154.6460	183.6020	247.6260	201.7780	199.0700	196.5320	147.4200	155.1100	181.7060	167.1100	169.9180	171.5200	115.5320	158.9720	172.4880	177.5720	146.6000	147.6360	171.8860	177.1840	168.4140	199.0600	203.9340	190.8520	165.0460	178.4300	120.1520	131.7580	142.4960	130.7100	127.5680
Fumarate	7.1860	3.8200	7.9200	4.1680	4.1060	6.8000	4.0080	3.0960	4.8200	3.4600	3.7460	2.3940	2.9060	3.4520	3.0300	2.9460	2.6480	2.9460	3.2860	3.1100	3.4940	5.1100	2.9740	3.3840	3.4860	3.1180	3.0180	3.6140	3.4920	3.0600	2.8020	2.1100	3.7700	3.4100	3.5660	3.7080	3.3540	3.6680	4.8900	4.3280	4.2320	4.2300	6.8900	3.2260	4.0300	3.9120	3.5520	6.3040	3.2600	2.8620
Glutamate	57.0500	54.7060	45.9340	58.9840	73.8800	80.7760	71.2100	79.5640	98.3060	73.7480	52.4560	59.4120	60.5440	60.0440	52.7920	73.7760	72.6500	56.4580	62.0920	72.5680	50.5660	98.1840	56.5140	67.0200	57.4540	68.4160	67.2560	90.0740	56.5780	94.6560	49.8300	43.6280	64.3660	57.2660	59.5160	62.6920	67.9480	72.2480	72.0320	87.1480	46.7540	74.0740	54.3420	61.8140	67.5700	52.7940	63.3780	61.3820	55.1440	37.6200
Isocitrate	5.3200	5.0640	3.9560	3.8160	7.0280	2.7060	3.5020	2.9000	3.8180	3.4860	4.2940	2.6480	4.9520	4.2860	5.7720	4.3760	1.8660	3.3420	3.1940	2.5860	4.5120	6.7220	4.1980	5.1580	5.7620	2.2520	2.2600	3.1240	3.4120	3.9900	2.9640	3.6620	3.9040	3.1600	4.4880	3.8860	3.4020	4.1860	3.8460	3.1640	3.9960	4.5680	2.3280	4.6720	4.1960	1.6080	2.1340	3.5920	2.4800	2.6500
Ketoglutarate	23.6760	16.5420	18.9520	16.3980	15.1580	17.2560	18.4600	16.4740	19.2060	18.6560	14.9360	11.6260	15.8900	15.0380	14.8600	17.6340	14.6140	14.6780	15.1400	17.3520	14.1880	15.4760	14.5300	14.0600	15.1580	12.8040	15.8960	15.7340	19.0680	18.3280	12.0180	8.2360	17.9320	14.6980	14.2120	15.6200	12.1000	16.8360	17.9280	14.9580	15.0300	17.1900	15.2460	13.7840	15.4700	10.7800	16.3420	16.4600	15.3080	14.6880
Lactate	1284.9200	1070.3880	1023.4600	1267.5260	1182.4140	841.7760	1572.6320	926.2680	1246.9220	1085.7200	1047.3000	959.5320	920.9320	888.2260	1003.9680	852.2300	896.1980	1110.6860	973.9140	1080.9120	1088.8760	1019.2980	1066.4820	1050.8620	952.7820	960.4600	1002.4320	985.4820	1332.4280	1029.3620	911.9960	605.1800	1269.7220	1051.4200	1076.6320	1367.9260	1349.0820	1144.1040	1046.4820	933.5340	1184.1500	1046.7960	1242.9320	1151.4900	1173.6140	893.3860	1194.2760	1125.5240	1050.3800	1289.7780
Malate	17.9540	11.4340	14.1600	11.4620	11.8560	9.8400	12.2140	7.4680	14.2420	9.1380	10.1080	6.4120	9.5160	10.3900	9.2020	8.6360	5.6760	7.3580	7.4560	7.5380	8.8260	13.6560	8.7060	9.9620	9.8520	6.8940	7.8980	8.3780	11.9480	8.5560	7.5160	5.9260	11.4740	9.6820	10.7080	8.8480	7.9180	10.0560	8.6140	8.5900	14.3020	11.4760	12.7580	9.2840	11.7080	28.1120	10.8000	11.2380	8.2080	8.4560
Oxaloacetate	0.7800	0.6540	3.6960	0.2740	0.4340	2.6860	0.7740	0.8200	1.1020	0.7120	0.5920	0.7540	0.5900	0.6440	0.6100	0.8040	0.8080	1.0940	1.1080	0.9180	0.6980	0.7940	0.7180	0.4660	0.6100	0.8980	0.7300	0.7920	0.8280	0.5700	1.5080	1.0020	1.2240	1.4420	0.8840	0.4440	0.4660	0.3680	0.4120	0.4920	0.5740	0.9880	2.0340	0.3420	0.3120	1.9740	1.9340	1.9480	1.1260	0.9420
Succinate	6.1940	3.8620	7.6580	4.1540	7.2200	6.2540	3.5080	2.9740	8.4880	3.9820	3.6160	2.7340	3.0360	3.3020	3.1600	3.6260	2.9100	3.7680	4.3400	3.9320	3.6520	7.5340	3.0240	4.5800	3.3020	3.8780	4.2740	5.1380	4.6160	3.4580	2.4400	3.2620	3.5660	3.6220	5.9400	4.1900	6.4580	4.9160	4.6940	4.3320	4.3280	3.9920	5.1520	3.2740	4.8820	2.4760	3.0580	6.8700	3.1100	2.7600
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	pubchem_id	inchi_key	kegg_id	other_id	other_id_type	ri	ri_type	moverz_quant	
2-Hydroxyglutarate						9.98		433	
Aspartate						9.37		418	
cis-aconitate						14.08		459	
Citrate						14.09		591	
Fumarate						6.13		287	
Glutamate						10.58		432	
Isocitrate						14.09		591	
Ketoglutarate						8.37		360	
Lactate						4.18		261	
Malate						8.93		419	
Oxaloacetate						8.37		346	
Succinate						5.19		289	
METABOLITES_END
#END